Product Description
The fumarate salt form of the mineral iron. Administration of ferrous fumarate results in elevation of serum iron concentration, which is then assimilated into hemoglobin, required for the transport of oxygen, or trapped in the reticuloendothelial cells for storage. This agent is used as a dietary supplement, and to prevent or treat iron deficiency related syndromes. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ferrous-fumarate)
Mechanisms of Action: Hemoglobin Binder
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | France | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Latvia | Lebanon | Lithuania | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Philippines | Portugal | Romania | Serbia | Slovakia | Slovenia | South Africa | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Pregnancy Outcomes | Pregnancy Outcomes
Known Adverse Events: Depressive Disorder | Abdominal Pain | Headache | Pain Unspecified | Injuries/wounds Unspecified | Candidiasis | Vaginitis | Weight Gain
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|